PMID- 24436987
OWN - NLM
STAT- MEDLINE
DCOM- 20140815
LR  - 20220316
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 720
IP  - 1-3
DP  - 2013 Nov 15
TI  - Protective effects of chronic resveratrol treatment on vascular inflammatory 
      injury in steptozotocin-induced type 2 diabetic rats: role of NF-kappa B 
      signaling.
PG  - 147-57
AB  - Type 2 diabetes mellitus (T2DM) is associated with an increased risk of 
      macrovascular disease. Epidemiological studies suggest that plant polyphenol 
      resveratrol (REV) is associated with reduced risk of cardiovascular diseases. 
      Since chronic inflammatory and endotheliar cell activation play a critical role 
      in vascular aging and atherogenesis, we evaluated whether REV can inhibit 
      inflammatory-induced vascular injury in T2DM. We found that REV (50 mg/kg/d) can 
      regulate glucose and lipid metabolism, improve insulin resistance and vascular 
      permeability, and protect against the foam cells and cholesterol crystals 
      formation in arterial vessel walls of T2DM rats. The protective effects of REV 
      were consistent with the decrease in nuclear translocation of nuclear factor 
      kappa B (NF-kappa B) and there down-regulation of interleukin-1 beta (IL-1beta) and 
      interleukin-6 (IL-6) levers in blood and tumor necrosis factor-alpha (TNF-alpha), 
      intercellular adhesion molecule-1 (ICAM-1), and monocyte chemoattractant 
      protein-1 (MCP-1) expressions in vascular wall. In addition, REV (10 and 100 
      nmol/L) treatment protected cultured endothelial cells against increases in the 
      expression of TNF-alpha, ICAM-1, and MCP-1 mRNA and protein induced by high glucose 
      via inhibiting nuclear translocation of NF-kappa B p65. The specific NF-kappa B 
      inhibitor pyrrolidine dithiocarbamate- (PDTC-) or small interfering RNA directed 
      against NF-kappa B p65-mediated downregulation of NF-kappa B p65 was further 
      enhanced by REV (100 nmol/L) in the human endothelial cell line EZ.hy926. In 
      conclusion, these observations suggest that chronic treatment of T2DM rats with 
      REV attenuates the inflammatory injury of the vascular wall and the effects are 
      associated with down-regulation of the NF-kappa B signal pathway.
FAU - Zheng, Xiaoying
AU  - Zheng X
FAU - Zhu, Shenyin
AU  - Zhu S
FAU - Chang, Shufang
AU  - Chang S
FAU - Cao, Yanni
AU  - Cao Y
FAU - Dong, Jie
AU  - Dong J
FAU - Li, Juan
AU  - Li J
FAU - Long, Rui
AU  - Long R
FAU - Zhou, Yuanda
AU  - Zhou Y
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Interleukin-1beta)
RN  - 0 (Interleukin-6)
RN  - 0 (Lipids)
RN  - 0 (NF-kappa B)
RN  - 0 (Stilbenes)
RN  - Q369O8926L (Resveratrol)
SB  - IM
MH  - Animals
MH  - Aorta, Thoracic/drug effects/injuries/metabolism/pathology
MH  - Capillary Permeability/drug effects
MH  - Carotid Arteries/drug effects/metabolism/pathology
MH  - Carotid Artery Injuries/drug therapy/metabolism/pathology
MH  - Cell Line
MH  - Diabetes Mellitus, Experimental/drug therapy/*metabolism
MH  - Diabetes Mellitus, Type 2/drug therapy/*metabolism
MH  - Diet, High-Fat
MH  - Endothelial Cells/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*pharmacology/therapeutic use
MH  - Insulin/blood
MH  - Interleukin-1beta/blood
MH  - Interleukin-6/blood
MH  - Lipids/blood
MH  - Male
MH  - NF-kappa B/*metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Resveratrol
MH  - Stilbenes/*pharmacology/therapeutic use
EDAT- 2014/01/18 06:00
MHDA- 2014/08/16 06:00
CRDT- 2014/01/18 06:00
PHST- 2014/01/18 06:00 [entrez]
PHST- 2014/01/18 06:00 [pubmed]
PHST- 2014/08/16 06:00 [medline]
AID - S0014-2999(13)00793-0 [pii]
PST - ppublish
SO  - Eur J Pharmacol. 2013 Nov 15;720(1-3):147-57.